View in EDS

PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.

Saved in:
Bibliographic Details
Title: PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis.
Authors: Sandborn WJ; University of California-San Diego, San Diego, California., Mattheakis LC; Protagonist Therapeutics, Inc, Newark, California., Modi NB; Protagonist Therapeutics, Inc, Newark, California., Pugatch D; Finch Therapeutics, Inc, Somerville, Massachusetts., Bressler B; University of British Columbia, Vancouver, Canada., Lee S; University of Washington, Seattle, Washington., Bhandari R; Delta Research Partners, Bastrop, Louisiana., Kanwar B; Applied Molecular Transport, San Francisco, California., Shames R; Siolta, San Carlos, California., D'Haens G; Faculty of Medicine, University of Amsterdam, Amsterdam, the Netherlands., Schreiber S; University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany., Danese S; Humanitas University, Humanitas Research Hospital, Milan, Italy., Feagan B; Western University, Pomona, California and Alimentiv, Inc, London, Ontario, Canada., Pai RK; Mayo Clinic Arizona, Phoenix, Arizona., Liu DY; Protagonist Therapeutics, Inc, Newark, California., Gupta S; Protagonist Therapeutics, Inc, Newark, California. Electronic address: s.gupta@ptgx-inc.com.
Source: Gastroenterology [Gastroenterology] 2021 Dec; Vol. 161 (6), pp. 1853-1864.e10. Date of Electronic Publication: 2021 Aug 30.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0374630 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0012 (Electronic) Linking ISSN: 00165085 NLM ISO Abbreviation: Gastroenterology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1528-0012
DOI:10.1053/j.gastro.2021.08.045